

### **AMENDMENTS TO THE DRAWINGS**

Please replace the Drawing Sheets as originally filed with the attached seven (7) pages of Replacement Drawing Sheets.

The Replacement Drawing Sheets have been amended to list the proper figure designations, i.e., FIG. 1A – FIG. 1G.

Additionally, the multiple alignment of the amino acid sequences presented in Figures 1A – 1G has been reformatted in the Replacement Drawing Sheets so that each section of the multiple alignment is presented on a single page, and not split up between two adjacent pages.

### **REMARKS**

Claims 17-29 are now pending, with Claim 17 being the sole independent claim.

Claims 1-16 have been cancelled without prejudice to or disclaimer of the subject matter recited therein.

Claims 17-29 have been added.

Support for the term "Myb-related transcription factor activity" in Claim 17 is found in the specification at least in Example 7, pages 32-33. Support for the Clustal V pairwise alignment default parameters, cited in Claim 17, and for the percent sequence identities cited in Claims 17-20, is found in the specification at least in the paragraph on page 11, lines 14-34.

Support for Claims 21-22 is found in the specification at least in the paragraph beginning at line 37 of page 3, and continuing through line 9 of page 4.

Support for Claim 23 is found in the specification at least in the paragraph at page 18, lines 1-11.

Support for Claim 24 is found in the specification at least in the paragraphs at page 4, lines 10-11, and page 15, lines 34-37.

Support for Claims 25-26 is found in the specification at least in Example 6, pages 31-32.

Support for Claims 27-29 is found in the specification at least in Examples 4-5, pages 28-31.

The specification has been amended on page 1, lines 3-4, to cite the prior applications for which benefit is claimed.

The specification has been amended at two paragraphs to replace reference to "Figure 1" with the term --Figures 1A-1G--.

The specification has been amended at two paragraphs to remove reference to hyperlinks.

A replacement to Figure 1 is submitted herewith. The seven replacement pages have been labeled Figures 1A-1G, and are formatted so each section of the multiple alignment of the amino acid sequences is presented on a single page, and not broken up between adjacent pages.

A substitute Sequence Listing is submitted herewith. The substitute Sequence Listing contains the following amendments: 1) line <130> now lists the docket number of the current application; 2) lines <140> and <141> list the application number and filing date, respectively, of the current application; 3) new lines <150> and <151> have been added to list the application number and filing dates, respectively, of two previous applications to which benefit is claimed; 4) the format

has been corrected for the <150> and <151> lines concerning the provisional application for which benefit is claimed; 5) lines <223> have been added, where appropriate, to define "unsure" nucleotide residues as --n is a, c, g or t--; 6) lines <223> have been added, where appropriate, to define "UNSURE" amino acid residues as -- Xaa can be any naturally occurring amino acid--.

No new matter has been added.



**RESPONSE TO RESTRICTION REQUIREMENT**

Applicants hereby elect, without traverse, Group I, Claims 1-9 and 16, drawn to an isolated polynucleotide encoding a polypeptide, a chimeric, and host cell, classified in class 536, subclass 23.6, for example, and SEQ ID NO:35, encoding SEQ ID NO:36.

Applicants believe new claims 17-29 to be directed to Group I.

Please charge any fees or credit any overpayment of fees which are required in connection herewith to Deposit Account No. 04-1928 (E. I. du Pont de Nemours and Company).

Allowance of the above-referenced application is respectfully requested.

Respectfully submitted,

**EMIL M. OROZCO, JR.**  
AGENT FOR APPLICANTS  
Registration No. 50,823  
Telephone: 302-695-3121  
Facsimile: 302-892-1026

Dated: September 12, 2005